Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins
Abstract
:1. Respiratory Viruses
2. Novel Vaccines
3. Novel Drugs
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wang, X.; Li, Y.; O’Brien, K.L.; Madhi, S.A.; Widdowson, M.A.; Byass, P.; Omer, S.B.; Abbas, Q.; Ali, A.; Amu, A.; et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study. Lancet Glob. Health 2020, 8, e497–e510. [Google Scholar] [CrossRef] [Green Version]
- Shi, T.; Arnott, A.; Semogas, I.; Falsey, A.R.; Openshaw, P.; Wedzicha, J.A.; Campbell, H.; Nair, H.; Investigators, R. The etiological role of common respiratory viruses in acute respiratory infections in older adults: A systematic review and meta-analysis. J. Infect. Dis. 2020, 222, S563–S569. [Google Scholar] [CrossRef]
- West, J.V. Acute upper airway infections. Br. Med. Bull. 2002, 61, 215–230. [Google Scholar] [CrossRef] [Green Version]
- Chatterjee, A.; Mavunda, K.; Krilov, L.R. Current state of respiratory syncytial virus disease and management. Infect. Dis. Ther. 2021, 3, 1–12. [Google Scholar]
- Tin Tin Htar, M.; Yerramalla, M.S.; Moisi, J.C.; Swerdlow, D.L. The burden of respiratory syncytial virus in adults: A systematic review and meta-analysis. Epidemiol. Infect. 2020, 148, e48. [Google Scholar] [CrossRef] [PubMed]
- Henderson, F.W.; Collier, A.M.; Clyde, W.A., Jr.; Denny, F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 1979, 300, 530–534. [Google Scholar] [CrossRef] [PubMed]
- Johnson, K.M.; Bloom, H.H.; Mufson, M.A.; Chanock, R.M. Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N. Engl. J. Med. 1962, 267, 68–72. [Google Scholar] [CrossRef] [PubMed]
- Bender, B.S.; Small, P.A., Jr. Influenza: Pathogenesis and host defense. Semin. Respir. Infect. 1992, 7, 38–45. [Google Scholar]
- Szewczuk, M.R.; Wade, A.W. Aging and the mucosal-associated lymphoid system. Ann. N. Y. Acad. Sci. 1983, 409, 333–344. [Google Scholar] [CrossRef] [PubMed]
- Efstathiou, C.; Abidi, S.H.; Harker, J.; Stevenson, N.J. Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics. Cell Mol. Life Sci. 2020, 77, 5045–5058. [Google Scholar] [CrossRef]
- Coultas, J.A.; Smyth, R.; Openshaw, P.J. Respiratory syncytial virus (rsv): A scourge from infancy to old age. Thorax 2019, 74, 986–993. [Google Scholar] [CrossRef] [Green Version]
- Griffiths, C.; Drews, S.J.; Marchant, D.J. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. Clin. Microbiol. Rev. 2017, 30, 277–319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mejias, A.; Rodriguez-Fernandez, R.; Oliva, S.; Peeples, M.E.; Ramilo, O. The journey to a respiratory syncytial virus vaccine. Ann. Allergy Asthma Immunol. 2020, 125, 36–46. [Google Scholar] [CrossRef]
- Boyoglu-Barnum, S.; Chirkova, T.; Anderson, L.J. Biology of infection and disease pathogenesis to guide rsv vaccine development. Front. Immunol. 2019, 10, 1675. [Google Scholar] [CrossRef] [PubMed]
- Collins, P.L.; Melero, J.A. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res. 2011, 162, 80–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Becker, Y. Respiratory syncytial virus (rsv) evades the human adaptive immune system by skewing the th1/th2 cytokine balance toward increased levels of th2 cytokines and ige, markers of allergy—A review. Virus Genes 2006, 33, 235–252. [Google Scholar] [CrossRef] [PubMed]
- Eichinger, K.M.; Kosanovich, J.L.; Lipp, M.; Empey, K.M.; Petrovsky, N. Strategies for active and passive pediatric rsv immunization. Ther. Adv. Vaccines Immunother. 2021, 9, 2515135520981516. [Google Scholar] [PubMed]
- Boyoglu-Barnum, S.; Tripp, R.A. Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opin. Biol. Ther. 2020, 20, 1073–1082. [Google Scholar] [CrossRef]
- Lukacs, N.W.; Malinczak, C.A. Harnessing cellular immunity for vaccination against respiratory viruses. Vaccines (Basel) 2020, 8, 783. [Google Scholar] [CrossRef]
- Durbin, J.E.; Durbin, R.K. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol. 2004, 17, 370–380. [Google Scholar] [CrossRef] [PubMed]
- Blanco, J.C.G.; Boukhvalova, M.S.; Morrison, T.G.; Vogel, S.N. A multifaceted approach to rsv vaccination. Hum. Vaccin. Immunother. 2018, 14, 1734–1745. [Google Scholar] [CrossRef] [PubMed]
- Graham, B.S.; Modjarrad, K.; McLellan, J.S. Novel antigens for rsv vaccines. Curr. Opin. Immunol. 2015, 35, 30–38. [Google Scholar] [CrossRef] [Green Version]
- Walsh, E.E.; Brandriss, M.W.; Schlesinger, J.J. Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J. Gen. Virol. 1987, 68 Pt 8, 2169–2176. [Google Scholar] [CrossRef]
- Phung, E.; Chang, L.A.; Morabito, K.M.; Kanekiyo, M.; Chen, M.; Nair, D.; Kumar, A.; Chen, G.L.; Ledgerwood, J.E.; Graham, B.S.; et al. Epitope-specific serological assays for rsv: Conformation matters. Vaccines (Basel) 2019, 7, 23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jordan, E.; Lawrence, S.J.; Meyer, T.P.H.; Schmidt, D.; Schultz, S.; Mueller, J.; Stroukova, D.; Koenen, B.; Gruenert, R.; Silbernagl, G.; et al. Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus based rsv vaccine. J. Infect. Dis. 2020, 29, 1062–1072. [Google Scholar]
- Khan, I.U.; Huang, J.; Li, X.; Xie, J.; Zhu, N. Nasal immunization with rsv f and g protein fragments conjugated to an m cell-targeting ligand induces an enhanced immune response and protection against rsv infection. Antiviral Res. 2018, 159, 95–103. [Google Scholar] [CrossRef] [PubMed]
- Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012, 380, 2095–2128. [Google Scholar] [CrossRef]
- Air, G.M. Influenza neuraminidase. Influenza Other Respir. Viruses 2012, 6, 245–256. [Google Scholar] [CrossRef]
- Houser, K.; Subbarao, K. Influenza vaccines: Challenges and solutions. Cell Host Microbe 2015, 17, 295–300. [Google Scholar] [CrossRef] [Green Version]
- Coelingh, K.L.; Luke, C.J.; Jin, H.; Talaat, K.R. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev. Vaccines 2014, 13, 855–871. [Google Scholar] [CrossRef]
- Sautto, G.A.; Kirchenbaum, G.A.; Ross, T.M. Towards a universal influenza vaccine: Different approaches for one goal. Virol. J. 2018, 15, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Slaoui, M.; Hepburn, M. Developing safe and effective covid vaccines - operation warp speed’s strategy and approach. N. Engl. J. Med. 2020, 383, 1701–1703. [Google Scholar] [CrossRef]
- O’Callaghan, K.P.; Blatz, A.M.; Offit, P.A. Developing a sars-cov-2 vaccine at warp speed. JAMA 2020, 324, 437–438. [Google Scholar] [CrossRef] [PubMed]
- Marx, V. Coronavirus jolts labs to warp speed. Nat. Methods 2020, 17, 465–468. [Google Scholar] [CrossRef] [PubMed]
- Ho, R.J.Y. Warp-speed covid-19 vaccine development: Beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships. J. Pharm. Sci. 2021, 110, 615–618. [Google Scholar] [CrossRef]
- Moore, J.P.; Klasse, P.J. Covid-19 vaccines: “Warp speed” needs mind melds, not warped minds. J. Virol. 2020, 94, e01083–e01120. [Google Scholar] [CrossRef]
- Noor, R. Developmental status of the potential vaccines for the mitigation of the covid-19 pandemic and a focus on the effectiveness of the pfizer-biontech and moderna mrna vaccines. Curr. Clin. Microbiol. Rep. 2021, 1–8. [Google Scholar]
- Bettini, E.; Locci, M. Sars-cov-2 mrna vaccines: Immunological mechanism and beyond. Vaccines (Basel) 2021, 9, 147. [Google Scholar] [CrossRef]
- Shojaee, A.; Vahedian-Azimi, A.; Faizi, F.; Rahimi-Bashar, F.; Shahriary, A.; Galeh, H.E.G.; Nehrir, B.; Guest, P.C.; Sahebkar, A. Relationship between covid-19 and angiotensin-converting enzyme 2: A scoping review. Adv. Exp. Med. Biol. 2021, 1321, 53–68. [Google Scholar]
- Tompa, D.R.; Immanuel, A.; Srikanth, S.; Kadhirvel, S. Trends and strategies to combat viral infections: A review on fda approved antiviral drugs. Int. J. Biol. Macromol. 2021, 172, 524–541. [Google Scholar] [CrossRef]
- Leroy, H.; Han, M.; Woottum, M.; Bracq, L.; Bouchet, J.; Xie, M.; Benichou, S. Virus-mediated cell-cell fusion. Int. J. Mol. Sci. 2020, 21, 9644. [Google Scholar] [CrossRef] [PubMed]
- Verma, J.; Subbarao, N.; Rajala, M.S. Envelope proteins as antiviral drug target. J. Drug Target 2020, 28, 1046–1052. [Google Scholar] [CrossRef] [PubMed]
- Domachowske, J.B.; Anderson, E.J.; Goldstein, M. The future of respiratory syncytial virus disease prevention and treatment. Infect. Dis. Ther. 2021, 10, 47–60. [Google Scholar] [CrossRef] [PubMed]
- Jiang, S.; Li, R.; Du, L.; Liu, S. Roles of the hemagglutinin of influenza a virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell 2010, 1, 342–354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palese, P.; Tobita, K.; Ueda, M.; Compans, R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61, 397–410. [Google Scholar] [CrossRef]
- Kim, C.U.; Lew, W.; Williams, M.A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Mendel, D.B.; Tai, C.Y.; et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681–690. [Google Scholar] [CrossRef] [PubMed]
- von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Van Phan, T.; Smythe, M.L.; White, H.F.; Oliver, S.W.; et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418–423. [Google Scholar] [CrossRef]
- Burmeister, W.P.; Henrissat, B.; Bosso, C.; Cusack, S.; Ruigrok, R.W. Influenza b virus neuraminidase can synthesize its own inhibitor. Structure 1993, 1, 19–26. [Google Scholar] [CrossRef]
- Cass, L.M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharm. 1999, 36, 1–11. [Google Scholar] [CrossRef]
- Babu, Y.S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T.H.; Hutchison, T.L.; Elliott, A.J.; Parker, C.D.; et al. Bcx-1812 (rwj-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482–3486. [Google Scholar] [CrossRef]
- Barroso, L.; Treanor, J.; Gubareva, L.; Hayden, F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: Randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 2005, 10, 901–910. [Google Scholar] [PubMed]
- Davies, W.L.; Grunert, R.R.; Haff, R.F.; McGahen, J.W.; Neumayer, E.M.; Paulshock, M.; Watts, J.C.; Wood, T.R.; Hermann, E.C.; Hoffmann, C.E. Antiviral activity of 1-adamantanamine (amantadine). Science 1964, 144, 862–863. [Google Scholar] [CrossRef] [PubMed]
- Lamb, R.A. The structure, function, and pathobiology of the influenza a and b virus ion channels. Cold Spring Harb. Perspect. Med. 2020, 10, a038505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kikuchi, T.; Watanabe, A. Baloxavir heralds a new era in influenza virus biology. Respir. Investig. 2019, 57, 1–2. [Google Scholar] [CrossRef] [PubMed]
- Uyeki, T.M.; Bernstein, H.H.; Bradley, J.S.; Englund, J.A.; File, T.M.; Fry, A.M.; Gravenstein, S.; Hayden, F.G.; Harper, S.A.; Hirshon, J.M.; et al. Clinical practice guidelines by the infectious diseases society of america: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin. Infect. Dis. 2019, 68, 895–902. [Google Scholar] [CrossRef] [PubMed]
- Dong, G.; Peng, C.; Luo, J.; Wang, C.; Han, L.; Wu, B.; Ji, G.; He, H. Adamantane-resistant influenza a viruses in the world (1902–2013): Frequency and distribution of m2 gene mutations. PLoS ONE 2015, 10, e0119115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lackenby, A.; Besselaar, T.G.; Daniels, R.S.; Fry, A.; Gregory, V.; Gubareva, L.V.; Huang, W.; Hurt, A.C.; Leang, S.K.; Lee, R.T.C.; et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res. 2018, 157, 38–46. [Google Scholar] [CrossRef] [PubMed]
- Zambon, M.; Hayden, F.G. Position statement: Global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001, 49, 147–156. [Google Scholar] [CrossRef]
- Checkmahomed, L.; Padey, B.; Pizzorno, A.; Terrier, O.; Rosa-Calatrava, M.; Abed, Y.; Baz, M.; Boivin, G. In Vitro combinations of baloxavir acid and other inhibitors against seasonal influenza a viruses. Viruses 2020, 12, 1139. [Google Scholar] [CrossRef]
- Mifsud, E.J.; Hayden, F.G.; Hurt, A.C. Antivirals targeting the polymerase complex of influenza viruses. Antivir. Res. 2019, 169, 104545. [Google Scholar] [CrossRef]
- Kumar, P.; Sah, A.K.; Tripathi, G.; Kashyap, A.; Tripathi, A.; Rao, R.; Mishra, P.C.; Mallick, K.; Husain, A.; Kashyap, M.K. Role of ace2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in covid-19. Mol. Cell Biochem. 2021, 476, 553–574. [Google Scholar] [CrossRef] [PubMed]
- Wang, R.; Stephen, P.; Tao, Y.; Zhang, W.; Lin, S.X. Human endeavor for anti-sars-cov-2 pharmacotherapy: A major strategy to fight the pandemic. Biomed. Pharmacother. 2021, 137, 111232. [Google Scholar] [CrossRef] [PubMed]
- Elshabrawy, H.A. Sars-cov-2: An update on potential antivirals in light of sars-cov antiviral drug discoveries. Vaccines (Basel) 2020, 8, 335. [Google Scholar] [CrossRef] [PubMed]
- Franchini, M.; Liumbruno, G.M. Convalescent plasma for the treatment of severe covid-19. Biologics 2021, 15, 31–38. [Google Scholar]
- Cohen, S.A.; Kellogg, C.; Equils, O. Neutralizing and cross-reacting antibodies: Implications for immunotherapy and sars-cov-2 vaccine development. Hum. Vaccin. Immunother. 2021, 17, 84–87. [Google Scholar] [CrossRef] [PubMed]
- Serrao, V.H.B.; Lee, J.E. Freting over sars-cov-2: Conformational dynamics of the spike glycoprotein. Cell Host Microbe 2020, 28, 778–779. [Google Scholar] [CrossRef] [PubMed]
- Freitas, B.T.; Durie, I.A.; Murray, J.; Longo, J.E.; Miller, H.C.; Crich, D.; Hogan, R.J.; Tripp, R.A.; Pegan, S.D. Characterization and noncovalent inhibition of the deubiquitinase and deisgylase activity of sars-cov-2 papain-like protease. ACS Infect. Dis. 2020, 6, 2099–2109. [Google Scholar] [CrossRef] [PubMed]
- Naik, R.R.; Shakya, A.K. Therapeutic strategies in the management of covid-19. Front. Mol. Biosci. 2020, 7, 636738. [Google Scholar] [CrossRef] [PubMed]
- Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Korompoki, E.; Fotiou, D.; Migkou, M.; Tzanninis, I.G.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopoulos, M.A. Emerging treatment strategies for covid-19 infection. Clin. Exp. Med. 2020, 1–13. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tripp, R.A.; Stambas, J. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses 2021, 13, 625. https://doi.org/10.3390/v13040625
Tripp RA, Stambas J. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses. 2021; 13(4):625. https://doi.org/10.3390/v13040625
Chicago/Turabian StyleTripp, Ralph A., and John Stambas. 2021. "Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins" Viruses 13, no. 4: 625. https://doi.org/10.3390/v13040625